AstraZeneca PLC — Board/Management Information 2023

Apr 27, 2023

National Storage Mechanism | Additional information

RNS Number : 6059X

AstraZeneca PLC

27 April 2023

27 April 2023 07:05 BST

AstraZeneca Board Committee Changes

AstraZeneca PLC (the Company) announced today a number of Board Committee changes:

>    Michel Demaré will succeed Leif Johansson as Chair of the Nomination and Governance Committee, with effect from the conclusion of the Company's Annual General Meeting today, 27 April 2023.

>    Nazneen Rahman will become a member of the Remuneration Committee, effective 1 May 2023.

>    Euan Ashley will succeed Nazneen Rahman as Chair of the Science Committee, effective 1 June 2023.  Dr Rahman will remain as a member of the Science Committee.

>    Euan Ashley will become a member of the Nomination and Governance Committee, effective 1 June 2023.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPPUAGCUPWGMQ